

Abiraterone

Section

Hormones and antihormones
 Oral > Solid: 250 mg; 500 mg

Indications

Malignant neoplasms of prostate

Adalimumab

Section

Immunomodulators for non-malignant disease
 Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL

Indications

Axial spondyloarthritis

Juvenile idiopathic arthritis

Crohn disease site

Rheumatoid arthritis

Afatinib

Section

Targeted therapies

Indications

Therapeutic equivalent to [erlotinib](#) for

Other specified malignant neoplasms of bronchus or lung

All-trans retinoic acid

Section

Targeted therapies
 Oral > Solid: 10 mg capsule

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

Allopurinol

Section

Supportive medicines
 Oral > Solid: 100 mg tablet; 300 mg tablet

Indications

Tumour lysis syndrome

Anastrozole

Section

Hormones and antihormones
 Oral > Solid: 1 mg tablet

Indications

Malignant neoplasms of breast

Other specified malignant neoplasms of breast

Arsenic trioxide

Section

Cytotoxic medicines

Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

Asparaginase

Section

Cytotoxic medicines

Powder for injection: 10 000 IU in vial.

Parenteral > General injections > unspecified: 10000 IU in vial powder for injection

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Lymphoid leukaemia, NOS

Atezolizumab

Section

Immunomodulators

Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion

Indications

Other specified malignant neoplasms of bronchus or lung

Azathioprine

Section

Immunomodulators for non-malignant disease

Parenteral > General injections > IV: 100 mg in vial powder for injection (as sodium salt)

Oral > Solid: 50 mg

Indications

Failure or rejection of transplanted organs or tissues

Relapsing-remitting multiple sclerosis

Bendamustine

Section

Cytotoxic medicines

Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL

Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Follicular lymphoma

Bicalutamide

Section

Hormones and antihormones

Oral > Solid: 50 mg

Indications

Malignant neoplasms of prostate

Bleomycin

Section

Cytotoxic medicines

Parenteral > General injections > unspecified: 15 mg in vial (as sulfate)

Indications

Other specified malignant neoplasms of the ovary

Unspecified malignant neoplasms of ill-defined or unspecified sites

Germ cell tumour of testis

Hodgkin lymphoma

Kaposi sarcoma of unspecified primary site

Bortezomib

Section

Targeted therapies

Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection

Indications

Plasma cell myeloma

Calcium folinate

Section

Cytotoxic medicines

Oral > Solid: 15 mg tablet

Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule

Oral > Solid: 15 mg tablet; 5 mg tablet; 25 mg tablet

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant neoplasm metastasis in large intestine

Malignant trophoblastic neoplasms of placenta

Burkitt lymphoma including Burkitt leukaemia

Osteosarcoma of bone and articular cartilage of unspecified sites

Malignant neoplasms of rectum

Malignant neoplasms of colon

Capecitabine

Section

Cytotoxic medicines

Oral > Solid: 150 mg tablet; 500 mg tablet

Indications

Malignant neoplasms of colon

Malignant neoplasm metastasis in large intestine

Other specified malignant neoplasms of breast

Malignant neoplasms of rectum

Carboplatin

Section

Cytotoxic medicines

Parenteral > General injections > unspecified: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL

Indications

Other specified carcinomas of ovary

Other specified malignant neoplasms of bronchus or lung

Osteosarcoma of bone and articular cartilage of unspecified sites

Malignant neoplasms of breast

Malignant neoplasms of nasopharynx

Retinoblastoma

Malignant neoplasms of cervix uteri

Certolizumab pegol

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to adalimumab for

Axial spondyloarthritis

Therapeutic equivalent to adalimumab for

Juvenile idiopathic arthritis

Therapeutic equivalent to adalimumab for

Crohn disease site

Therapeutic equivalent to adalimumab for

Rheumatoid arthritis

Chlorambucil

Section

Cytotoxic medicines

Oral > Solid: 2 mg tablet

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Ciclosporin

Section

Immunomodulators for non-malignant disease

Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection

Oral > Solid: 25 mg

Indications

Failure or rejection of transplanted organs or tissues

Cisplatin

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL

Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection

Indications

Other specified malignant neoplasms of the ovary

Unspecified malignant neoplasms of ill-defined or unspecified sites

Osteosarcoma of bone and articular cartilage of unspecified sites

Germ cell tumour of testis

Other specified malignant neoplasms of bronchus or lung

Squamous cell carcinoma of oropharynx

Malignant neoplasms of cervix uteri

Malignant neoplasms of nasopharynx

Crizotinib

Section

Targeted therapies

Oral > Solid: 200 mg; 250 mg

Indications

Other specified malignant neoplasms of bronchus or lung

Cyclophosphamide

Section

Cytotoxic medicines

Oral > Solid: 25 mg tablet

Parenteral > General injections > unspecified: 500 mg in vial powder for injection

Parenteral > General injections > IV: 500 mg in vial powder for injection

Oral > Solid: 25 mg tablet; 50 mg tablet

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant trophoblastic neoplasms of placenta

Ewing sarcoma of bone and articular cartilage of unspecified sites

Follicular lymphoma

Other specified malignant neoplasms of breast

Lymphoid leukaemia, NOS

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Malignant neoplasms of breast

Rhabdomyosarcoma primary site

Hodgkin lymphoma

Plasma cell myeloma

Burkitt lymphoma including Burkitt leukaemia

Diffuse large B-cell lymphomas

Cytarabine

Section

Cytotoxic medicines

Parenteral > General injections > unspecified: 100 mg in vial powder for injection

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Burkitt lymphoma including Burkitt leukaemia

Lymphoid leukaemia, NOS

Acute myeloid leukaemia with recurrent genetic abnormalities

Myeloid leukaemia

Dacarbazine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 100 mg in vial powder for injection

Indications

Hodgkin lymphoma

Dactinomycin

Section

Cytotoxic medicines

Parenteral > General injections > IV: 500 µg in vial powder for injection

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant trophoblastic neoplasms of placenta

Malignant neoplasms of kidney, except renal pelvis

Rhabdomyosarcoma primary site

Dasatinib

Section

Targeted therapies

Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet

Indications

Chronic myeloid leukaemia, NOS

Daunorubicin

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial (hydrochloride) powder for injection

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

Lymphoid leukaemia, NOS

Myeloid leukaemia

Dexamethasone

Section

Hormones and antihormones

Oral > Solid: 4 mg

Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)

Oral > Liquid: 2 mg per 5 mL

Oral > Solid: 2 mg; 4 mg

Indications

Plasma cell myeloma

Lymphoid leukaemia, NOS

Docetaxel

Section

Cytotoxic medicines

Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL

Indications

Malignant neoplasms of prostate

Other specified malignant neoplasms of breast

Malignant neoplasms of breast

Unspecified malignant neoplasms of ill-defined or unspecified sites

Doxorubicin

Section

Cytotoxic medicines

Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant neoplasms of breast

Hodgkin lymphoma

Other specified malignant neoplasms of breast

Burkitt lymphoma including Burkitt leukaemia

Malignant neoplasms of kidney, except renal pelvis

Ewing sarcoma of bone and articular cartilage of unspecified sites

Follicular lymphoma

Osteosarcoma of bone and articular cartilage of unspecified sites

Lymphoid leukaemia, NOS

Plasma cell myeloma

Kaposi sarcoma of unspecified primary site

Diffuse large B-cell lymphomas

Enzalutamide

Section

Hormones and antihormones
Oral > Solid: 40 mg

Indications

Malignant neoplasms of prostate

Erlotinib

Section

Targeted therapies
Oral > Solid: 100 mg; 150 mg

Indications

Other specified malignant neoplasms of bronchus or lung

Etanercept

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to adalimumab for

Axial spondyloarthritis

Therapeutic equivalent to adalimumab for

Juvenile idiopathic arthritis

Therapeutic equivalent to adalimumab for

Crohn disease site

Therapeutic equivalent to adalimumab for

Rheumatoid arthritis

Etoposide

Section

Cytotoxic medicines
Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule
Oral > Solid: 100 mg capsule
Oral > Solid: 100 mg capsule; 50 mg capsule

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Other specified malignant neoplasms of bronchus or lung

Malignant trophoblastic neoplasms of placenta

Germ cell tumour of testis

Hodgkin lymphoma

Other specified malignant neoplasms of the ovary

Burkitt lymphoma including Burkitt leukaemia

Ewing sarcoma of bone and articular cartilage of unspecified sites

Lymphoid leukaemia, NOS

Retinoblastoma

Filgrastim

Section

Immunomodulators

Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial

Indications

Acquired neutropenias

Fingolimod

Section

Immunomodulators for non-malignant disease

Oral > Solid: 0.25 mg; 0.5 mg

Indications

Relapsing-remitting multiple sclerosis

Fludarabine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection

Oral > Solid: 10 mg tablet (fludarabine phosphate)

Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Fluorouracil

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule

Indications

Malignant neoplasms of breast

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of rectum

Malignant neoplasms of colon

Malignant neoplasms of nasopharynx

Gefitinib

Section

Targeted therapies

Indications

Therapeutic equivalent to erlotinib for

Other specified malignant neoplasms of bronchus or lung

Gemcitabine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection

Indications

Other specified carcinomas of ovary

Other specified malignant neoplasms of bronchus or lung

Glatiramer acetate

Section

Immunomodulators for non-malignant disease

Parenteral > General injections > SC: 20 mg per mL; 40 mg per mL

Indications

Relapsing-remitting multiple sclerosis

Golimumab

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to [adalimumab](#) for

Axial spondyloarthritis

Therapeutic equivalent to [adalimumab](#) for

Juvenile idiopathic arthritis

Therapeutic equivalent to [adalimumab](#) for

Crohn disease site

Therapeutic equivalent to [adalimumab](#) for

Rheumatoid arthritis

Hydrocortisone

Section

Hormones and antihormones

Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)

Indications

Lymphoid leukaemia, NOS

Unspecified malignant neoplasms of ill-defined or unspecified sites

Hydroxycarbamide

Section

Cytotoxic medicines

Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g

Indications

Squamous cell carcinoma of oropharynx

Chronic myeloid leukaemia, NOS

Ifosfamide

Section

Cytotoxic medicines

Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection

Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection

Indications

Other specified malignant neoplasms of the ovary

Ewing sarcoma of bone and articular cartilage of unspecified sites

Germ cell tumour of testis

Osteosarcoma of bone and articular cartilage of unspecified sites

Rhabdomyosarcoma primary site

Unspecified malignant neoplasms of ill-defined or unspecified sites

Imatinib

Section

Targeted therapies

Oral > Solid: 100 mg tablet; 400 mg tablet

Indications

Gastrointestinal stromal tumour of unspecified gastrointestinal sites

Chronic myeloid leukaemia, NOS

Infliximab

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to [adalimumab](#) for

Axial spondyloarthritis

Therapeutic equivalent to [adalimumab](#) for

Juvenile idiopathic arthritis

Therapeutic equivalent to [adalimumab](#) for

Crohn disease site

Therapeutic equivalent to [adalimumab](#) for

Rheumatoid arthritis

Irinotecan

Section

Cytotoxic medicines

Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial

Indications

Malignant neoplasm metastasis in large intestine

Lenalidomide

Section

Immunomodulators

Oral > Solid: 25 mg

Indications

Plasma cell myeloma

Leuprorelin

Section

Hormones and antihormones

Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe

Indications

Malignant neoplasms of prostate

Malignant neoplasms of breast

Melphalan

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial powder for injection

Oral > Solid: 2 mg

Indications

Plasma cell myeloma

Mercaptopurine

Section

Cytotoxic medicines

Oral > Solid: 50 mg tablet

Indications

Lymphoid leukaemia, NOS

Unspecified malignant neoplasms of ill-defined or unspecified sites

Acute myeloid leukaemia with recurrent genetic abnormalities

Mesna

Section

Supportive medicines

Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule

Oral > Solid: 400 mg; 600 mg

Indications

Osteosarcoma of bone and articular cartilage of other specified sites

Other specified malignant neoplasms of the ovary

Ewing sarcoma of bone and articular cartilage of unspecified sites

Germ cell tumour of testis

Rhabdomyosarcoma primary site

Unspecified malignant neoplasms of ill-defined or unspecified sites

Methotrexate

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial (as sodium salt)

Oral > Solid: 2.5 mg (as sodium salt)

Indications

Malignant neoplasms of breast

Malignant trophoblastic neoplasms of placenta

Osteosarcoma of bone and articular cartilage of unspecified sites

Lymphoid leukaemia, NOS

Unspecified malignant neoplasms of ill-defined or unspecified sites

Acute myeloid leukaemia with recurrent genetic abnormalities

Methylprednisolone

Section

Hormones and antihormones

Parenteral > General injections > IV: 40 mg per mL in 1 mL single-dose vial (as sodium succinate); 40 mg per mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per mL in 1 mL single-dose vial (as sodium succinate)

Indications

Lymphoid leukaemia, NOS

Nilotinib

Section

Targeted therapies

Oral > Solid: 150 mg capsule; 200 mg capsule

Indications

Chronic myeloid leukaemia, NOS

Nivolumab

Section

Immunomodulators

Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion

Indications

Melanoma of skin

Other specified malignant neoplasms of bronchus or lung

Ocrelizumab

Section

Immunomodulators for non-malignant disease

Parenteral > General injections > IV: 30 mg per mL in 10 mL vial

Indications

Relapsing-remitting multiple sclerosis

Oxaliplatin

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial

Indications

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of colon

Paclitaxel

Section

Cytotoxic medicines

Parenteral > General injections > IV: 6 mg per mL

Indications

Other specified malignant neoplasms of the ovary

Other specified malignant neoplasms of bronchus or lung

Kaposi sarcoma of unspecified primary site

Malignant neoplasms of nasopharynx

Other specified malignant neoplasms of breast

Other specified carcinomas of ovary

Malignant neoplasms of breast

Malignant neoplasms of cervix uteri

Pegaspargase

Section

Cytotoxic medicines

Parenteral > General injections > IV: 3750 units per 5 mL in vial

Indications

Lymphoid leukaemia, NOS

Pembrolizumab

Section

Immunomodulators

Parenteral > General injections > IV: 50 mg powder for injection

Indications

Therapeutic equivalent to nivolumab for

Melanoma of skin

Other specified malignant neoplasms of bronchus or lung

Pertuzumab

Section

Targeted therapies

Parenteral > General injections > IV: 240 mg per 14 mL in 14 mL vial concentrated solution

Indications

Carcinoma of breast, specialised type

Prednisolone

Section

Hormones and antihormones

Oral > Liquid: 5 mg per mL

Oral > Solid: 5 mg; 25 mg

Indications

Follicular lymphoma

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Diffuse large B-cell lymphomas

Hodgkin lymphoma

Unspecified malignant neoplasms of ill-defined or unspecified sites

Lymphoid leukaemia, NOS

Burkitt lymphoma including Burkitt leukaemia

Plasma cell myeloma

Malignant neoplasms of prostate

Procarbazine

Section

Cytotoxic medicines

Oral > Solid: 50 mg (as hydrochloride)

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Hodgkin lymphoma

Realgar-indigo naturalis formulation

Section

Cytotoxic medicines

Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

Rituximab

Section

Targeted therapies

Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial

Indications

Follicular lymphoma

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Diffuse large B-cell lymphomas

Tamoxifen

Section

Hormones and antihormones

Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)

Indications

Other specified malignant neoplasms of breast

Malignant neoplasms of breast

Thalidomide

Section

Immunomodulators

Oral > Solid: 50 mg

Indications

Plasma cell myeloma

Tioguanine

Section

Cytotoxic medicines

Oral > Solid: 40 mg

Indications

Lymphoid leukaemia, NOS

Trastuzumab

Section

Targeted therapies

Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection

Indications

Carcinoma of breast, specialised type

Trastuzumab emtansine

Section

Targeted therapies

Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection

Indications

Carcinoma of breast, specialised type

Vinblastine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)

Indications

Hodgkin lymphoma

Kaposi sarcoma of unspecified primary site

Germ cell tumour of testis

Other specified malignant neoplasms of the ovary

Unspecified malignant neoplasms of ill-defined or unspecified sites

Vincristine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Kaposi sarcoma of other specified primary sites

Malignant trophoblastic neoplasms of placenta

Malignant neoplasms of kidney, except renal pelvis

Ewing sarcoma of bone and articular cartilage of unspecified sites

Follicular lymphoma

Lymphoid leukaemia, NOS

Rhabdomyosarcoma primary site

Diffuse large B-cell lymphomas

Retinoblastoma

Hodgkin lymphoma

Burkitt lymphoma including Burkitt leukaemia

Vinorelbine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 50 mg per 5 mL in 5 mL vial

Indications

Other specified malignant neoplasms of bronchus or lung

Other specified malignant neoplasms of breast

Zoledronic acid

Section

Supportive medicines

Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle

Indications

Malignant neoplasm metastasis in bone or bone marrow